Six Upgrades to Guarantee L4 Self-Driving Operation! RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus
13.9.2022 18:00:00 EEST | Business Wire | Press release
RoboSense , a world-leading provider of Smart LiDAR Sensor Systems launched upgraded 128-beam LiDAR, RS-Ruby Plus , designed for autonomous driving commercial operation, and it debuted at CES2022. Nowadays, it obtained a large number of orders from multiple autonomous vehicle companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005763/en/
RS-Ruby Plus (Photo: Business Wire)
Breaking through the limitations of the previous generation RS-Ruby，the RS-Ruby Plus adopts a new modular architecture design, which reduces its size and weight by 50% compared with the previous generation, and reduces power consumption to 30W, which is 33% lower than RS-Ruby. In the past two years, RS-Ruby has supported Momenta, IdriverPlus, DeepRoute.ai, AutoX, Mushroom Car Alliance and over thousands RoboTaxi fleets in pilot commercial operations with its stable and reliable operation performance.
Six Upgrades of RS-Ruby Plus：
1. Automotive-grade design for reliability as the reference
RoboSense developed a new architecture design for RS-Ruby Plus with reference to automotive-grade standards to ensure that the product passes tens of automotive-grade reliability tests including mechanical shock, random vibration, low temperature operation, high-pressure water impact and EMC.
Watch：RS-Ruby Plus passed dozens of reliability tests
2. Comprehensively improve the perception distance
RoboSense achieved a breakthrough in the detection range of 905nm LiDAR on the premise of ensured safety of human eyes. The product reached a super detection range of 240m @10% standard reflectivity (under 100,000 Lux sunlight environment) and the overall detection range performance improved by 20%.
In the high-performance mode, Ruby Plus can increase the horizontal angular resolution of 128 channels from 0.2° to 0.1° at 10Hz refresh rate, thus providing more point cloud information in the horizontal direction. Meanwhile, 104 channels 0.1° vertical resolution, including 32 channels ultra-long detection range. RS-Ruby Plus detects cars at 218 meters with 4 lines and 13 points.
Watch：RS-Ruby Plus point cloud in various scenarios
3. Detection capability of black-painted vehicles boosted
Empowered by the super detection range capability, RS-Ruby Plus greatly improving the detection and recognition capabilities of perception for black vehicles.
The road line detection capability of RS-Ruby Plus has been improved, it stably detects 85-90 meters, thus further improving the safety and user experience of autonomous vehicles when changing lanes and going up and down ramps.
4. Higher accuracy and finer imaging
Detection range accuracy improvement of RS-Ruby Plus
- Near-field area 0.4~3m, accuracy up to ±3cm (@100,000 Lux lighting environment)
- Far-field area 3~240m, accuracy up to ±2cm (@100,000 Lux lighting environment)
The higher accuracy of LiDAR, the more precise and clear the shape of small objects like stone piers, lampposts and traffic cones can be restored.
5. Comprehensive anti-interference
RS-Ruby Plus uses the latest laser encryption technology, RS-Ruby Plus effectively resists interference from other LiDARs and ambient light and sunlight (100,000 Lux lighting).
6. Automotive Ethernet, gPTP, PTP
RS-Ruby Plus has automotive Ethernet interface. The product supports both GPS synchronization and network synchronization (PTP and gPTP time synchronization) protocols, which greatly reduces data transmission delay and simplifies cable layout.
RoboSense will always employ more advanced technology innovations and feature ever superior performance to empower industry partners, support the comprehensive commercialization of autonomous driving.
Read More: RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005763/en/
Contact information
Grace Ye
Media@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom